"The
Report Hepatitis B Virus (HBV) Therapeutics - Japan Drug Forecast and
Market Analysis to 2024 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Chronic
hepatitis B virus (HBV)
infection is a serious chronic liver disease caused by the failure of
viral clearance following acute HBV infection. Despite the
availability of effective prophylactic vaccines, the disease remains
a serious global health concern, with estimated over 350 million
people worldwide currently living with this condition. In addition,
patients with chronic hepatitis B are at a high risk of developing
life-threatening complications including liver cirrhosis and
hepatocellular carcinoma (HCC). In 2010, an estimated 786,000
HBV-related deaths occurred worldwide.
Available
treatment for chronic hepatitis B focuses on viral suppression, and
include oral nucleos(t)ide analogues (NAs) and pegylated interferon
(PEG-IFN). The two therapy classes have distinctive strengths and
weaknesses. Nevertheless, most patients are using long-term NA
treatment, and suffer from issues such as high accumulated treatment
cost and low compliance.
The
Japanese chronic hepatitis B therapeutic market was valued at $150.5m
in 2014. The launch of new therapies will strongly drive the growth
of the Japanese chronic hepatitis B market over the forecast period,
with GlobalData expecting the market entries of Gileads TAF,
Arrowheads ARC-520, and Gileads GS-9620 in 2020, 2023, and 2024,
respectively. The approval of these drugs will occur later than in
the US, which will limit the impact of the sales of the new therapies
in Japan.
Download Sample copy of this
Report at
Scope
- Overview of HBV including
epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
- Detailed information on the
key drugs in Japan including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in Japan from 2014-2024.
- Analysis of the impact of key
events as well the drivers and restraints affecting Japan HBV market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for HBV.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2014-2024 in Japan.
Read our latest Press
Release at http://www.marketresearchreports.biz/pressreleases
Table of Contents
1 Table of Contents 2
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Overview
3.2 Etiology and
Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.3 Symptoms
3.4 Prognosis
3.4.1 Phases of Chronic HBV
Infection
3.4.2 Complications of Chronic
Hepatitis B
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment
Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and
Leading Prescribed Drugs
4.1.3 Clinical Practice
4.2 Japan
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major
Brands
5.2.1 Baraclude (entecavir)
5.2.2 Viread (tenofovir
disoproxil fumarate)
5.2.3 Pegasys (peginterferon
alfa-2a)
5.2.4 Hepsera (adefovir
dipivoxil)
5.2.5 Tyzeka (telbivudine)
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment